Protein kinase C-iota-mediated glycolysis promotes non-small-cell lung cancer progression

References

• Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–289. doi:10.3322/caac.2134927253694
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.2144229313949
   PubMed Web of Science ®Google Scholar
• Faubert B, Li KY, Cai L, et al. Lactate metabolism in human lung tumors. Cell. 2017;171(2):358–371e359. doi:10.1016/j.cell.2017.09.01928985563
   PubMed Web of Science ®Google Scholar
• Yildirim F, Yurdakul AS, Ozkaya S, Akdemir UO, Ozturk C. Total lesion glycolysis by 18F-FDG PET/CT is independent prognostic factor in patients with advanced non-small cell lung cancer. Clin Respir J. 2017;11(5):602–611. doi:10.1111/crj.1239126434685
   PubMed Web of Science ®Google Scholar
• Warburg O. [Origin of cancer cells]. Oncologia. 1956;9(2):75–83.13335077
   PubMedGoogle Scholar
• Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer. 2013;12:152. doi:10.1186/1476-4598-12-15224298908
   PubMed Web of Science ®Google Scholar
• Newton AC. Protein kinase C: perfectly balanced. Crit Rev Biochem Mol Biol. 2018;53(2):208–230. doi:10.1080/10409238.2018.144240829513138
   PubMed Web of Science ®Google Scholar
• Fan C, Li Y, Jia J. Protein kinase Cs in lung cancer: a promising target for therapies. J Cancer Res Ther. 2013;9 Suppl 2:S74–79. doi:10.4103/0973-1482.11910224135246
   PubMed Web of Science ®Google Scholar
• Isakov N. Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression. Semin Cancer Biol. 2018;48:36–52. doi:10.1016/j.semcancer.2017.04.01228571764
   PubMed Web of Science ®Google Scholar
• Regala RP, Weems C, Jamieson L, Copland JA, Thompson EA, Fields AP. Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity. J Biol Chem. 2005;280(35):31109–31115. doi:10.1074/jbc.M50540220015994303
   PubMed Web of Science ®Google Scholar
• Sarkar S, Bristow CA, Dey P, et al. PRKCI promotes immune suppression in ovarian cancer. Genes Dev. 2017;31(11):1109–1121. doi:10.1101/gad.296640.11728698296
   PubMed Web of Science ®Google Scholar
• Troy A, Cadwallader AB, Fedorov Y, Tyner K, Tanaka KK, Olwin BB. Coordination of satellite cell activation and self-renewal by Par-complex-dependent asymmetric activation of p38alpha/beta MAPK. Cell Stem Cell. 2012;11(4):541–553. doi:10.1016/j.stem.2012.05.02523040480
   PubMed Web of Science ®Google Scholar
• Rosse C, Lodillinsky C, Fuhrmann L, et al. Control of MT1-MMP transport by atypical PKC during breast-cancer progression. Proc Natl Acad Sci U S A. 2014;111(18):E1872–1879. doi:10.1073/pnas.140074911124753582
   PubMed Web of Science ®Google Scholar
• Siska PJ, Rathmell JC. PKCs sweeten cell metabolism by phosphorylation of Glut1. Mol Cell. 2015;58(5):711–712. doi:10.1016/j.molcel.2015.05.02526046643
   PubMed Web of Science ®Google Scholar
• Szablewski L. Expression of glucose transporters in cancers. Biochim Biophys Acta. 2013;1835(2):164–169. doi:10.1016/j.bbcan.2012.12.00423266512
   PubMed Web of Science ®Google Scholar
• Mueckler M, Thorens B. The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013;34(2–3):121–138. doi:10.1016/j.mam.2012.07.00123506862
   PubMed Web of Science ®Google Scholar
• Mueckle M. Facilitative glucose transporters. Eur J Biochem. 1994;219:713–725.8112322
   PubMedGoogle Scholar
• de Geus-Oei LF, van Krieken JH, Aliredjo RP, et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer. 2007;55(1):79–87. doi:10.1016/j.lungcan.2006.08.01817046099
   PubMed Web of Science ®Google Scholar
• Zhao FQ, Keating AF. Functional properties and genomics of glucose transporters. Curr Genomics. 2007;8(2):113–128.18660845
   PubMed Web of Science ®Google Scholar
• Fenske W, Volker HU, Adam P, et al. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer. 2009;16(3):919–928. doi:10.1677/ERC-08-021119465749
   PubMed Web of Science ®Google Scholar
• Liu Y, Cao Y, Zhang W, et al. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther. 2012;11(8):1672–1682. doi:10.1158/1535-7163.MCT-12-013122689530
   PubMed Web of Science ®Google Scholar
• Kaira K, Serizawa M, Koh Y, et al. Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. Eur J Cancer. 2012;48(8):1244–1254. doi:10.1016/j.ejca.2012.01.01622330319
   PubMed Web of Science ®Google Scholar
• Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther. 2009;121(1):29–40. doi:10.1016/j.pharmthera.2008.09.00518992769
   PubMed Web of Science ®Google Scholar
• Ohno H, Nakatsu Y, Sakoda H, et al. 4F2hc stabilizes GLUT1 protein and increases glucose transport activity. Am J Physiol Cell Physiol. 2011;300(5):C1047–1054. doi:10.1152/ajpcell.00416.201021270293
   PubMed Web of Science ®Google Scholar
• Guo Z, Jia J, Yao M, et al. Diacylglycerol kinase gamma predicts prognosis and functions as a tumor suppressor by negatively regulating glucose transporter 1 in hepatocellular carcinoma. Exp Cell Res. 2018;373(1–2):211–220. doi:10.1016/j.yexcr.2018.11.00130399372
   PubMed Web of Science ®Google Scholar
• Li L, Liang Y, Kang L, et al. Transcriptional regulation of the warburg effect in cancer by SIX1. Cancer Cell. 2018;33(3):368–385e367. doi:10.1016/j.ccell.2018.01.01029455928
   PubMed Web of Science ®Google Scholar
• Osthus RC, Shim H, Kim S, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem. 2000;275(29):21797–21800. doi:10.1074/jbc.C00002320010823814
   PubMed Web of Science ®Google Scholar
• Riddell M, Nakayama A, Hikita T, et al. aPKC controls endothelial growth by modulating c-Myc via FoxO1 DNA-binding ability. Nat Commun. 2018;9(1):5357. doi:10.1038/s41467-018-07739-030559384
   PubMedGoogle Scholar
• Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol. 2001;2(3):157–164.11902566
   PubMed Web of Science ®Google Scholar
• Luo Q, Tang L, Lin H, et al. The oncogenic role of PKCiota gene amplification and overexpression in Chinese non-small cell lung cancer. Lung Cancer. 2014;84(2):190–195. doi:10.1016/j.lungcan.2013.08.02924636699
   PubMed Web of Science ®Google Scholar
• Tan Z, Yang C, Zhang X, Zheng P, Shen W. Expression of glucose transporter 1 and prognosis in non-small cell lung cancer: a pooled analysis of 1665 patients. Oncotarget. 2017;8(37):60954–60961. doi:10.18632/oncotarget.1760428977837
   PubMedGoogle Scholar
• Yan YF, Zheng YF, Ming PP, Deng XX, Ge W, Wu YG. Immune checkpoint inhibitors in non-small-cell lung cancer: current status and future directions. Brief Funct Genomics. 2019;18(2):147–156. doi:10.1093/bfgp/ely029
   PubMed Web of Science ®Google Scholar
• Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008;26(15):2442–2449. doi:10.1200/JCO.2007.14.849418458038
   PubMed Web of Science ®Google Scholar
• Pakkala S, Ramalingam SS. Personalized therapy for lung cancer: striking a moving target. JCI Insight. 2018;3(15). doi:10.1172/jci.insight.97941
   PubMed Web of Science ®Google Scholar
• Nakamura H, Saji H, Marushima H, et al. Standardized uptake values in the primary lesions of non-small-cell lung cancer in FDG-PET/CT can predict regional lymph node metastases. Ann Surg Oncol. 2015;22 Suppl 3:S1388–1393. doi:10.1245/s10434-015-4564-625900205
   PubMed Web of Science ®Google Scholar
• Calandriello L, Larici AR, Leccisotti L, et al. Multifunctional assessment of non-small cell lung cancer: perfusion-metabolic correlation. Clin Nucl Med. 2018;43(1):e18–e24. doi:10.1097/RLU.000000000000188829189372
   PubMed Web of Science ®Google Scholar
• Lapa P, Oliveiros B, Marques M, et al. Metabolic tumor burden quantified on [(18)F]FDG PET/CT improves TNM staging of lung cancer patients. Eur J Nucl Med Mol Imaging. 2017;44(13):2169–2178. doi:10.1007/s00259-017-3789-y28785842
   PubMed Web of Science ®Google Scholar
• Justilien V, Walsh MP, Ali SA, Thompson EA, Murray NR, Fields AP. The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell. 2014;25(2):139–151. doi:10.1016/j.ccr.2014.01.00824525231
   PubMed Web of Science ®Google Scholar
• Atwood SX, Li M, Lee A, Tang JY, Oro AE. GLI activation by atypical protein kinase C iota/lambda regulates the growth of basal cell carcinomas. Nature. 2013;494(7438):484–488. doi:10.1038/nature1188923446420
   PubMed Web of Science ®Google Scholar
• Linch M, Sanz-Garcia M, Rosse C, et al. Regulation of polarized morphogenesis by protein kinase C iota in oncogenic epithelial spheroids. Carcinogenesis. 2014;35(2):396–406. doi:10.1093/carcin/bgt31324072773
   PubMed Web of Science ®Google Scholar
• Fields AP, Regala RP. Protein kinase C iota: human oncogene, prognostic marker and therapeutic target. Pharmacol Res. 2007;55(6):487–497.17570678
   PubMed Web of Science ®Google Scholar
• Wang Y, Justilien V, Brennan KI, Jamieson L, Murray NR, Fields AP. PKCiota regulates nuclear YAP1 localization and ovarian cancer tumorigenesis. Oncogene. 2017;36(4):534–545. doi:10.1038/onc.2016.22427321186
   PubMed Web of Science ®Google Scholar
• Dejure FR, Eilers M. MYC and tumor metabolism: chicken and egg. Embo J. 2017;36(23):3409–3420. doi:10.15252/embj.20179643829127156
   PubMed Web of Science ®Google Scholar
• Fields AP, Ali SA, Justilien V, Murray NR. Targeting oncogenic protein kinase Ciota for treatment of mutant KRAS LADC. Small GTPases. 2017;8(1):58–64. doi:10.1080/21541248.2016.119495327245608
   PubMedGoogle Scholar
• Mansfield AS, Fields AP, Jatoi A, et al. Phase I dose escalation study of the PKCiota inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer. Anticancer Drugs. 2013;24(10):1079–1083. doi:10.1097/CAD.000000000000000923962904
   PubMed Web of Science ®Google Scholar
• Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn. 2013;15(4):415–453. doi:10.1016/j.jmoldx.2013.03.00123562183
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–892. doi:10.1056/NEJMoa111320522397650
   PubMed Web of Science ®Google Scholar
• Mountain CF, Lukeman JM, Hammar SP, et al. Lung cancer classification: the relationship of disease extent and cell type to survival in a clinical trials population. J Surg Oncol. 1987;35(3):147–156.3037195
   PubMed Web of Science ®Google Scholar
• Goodwin J, Neugent ML, Lee SY, et al. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition. Nat Commun. 2017;8:15503. doi:10.1038/ncomms1550328548087
   PubMed Web of Science ®Google Scholar
• Koh YW, Lee SJ, Park SY. Differential expression and prognostic significance of GLUT1 according to histologic type of non-small-cell lung cancer and its association with volume-dependent parameters. Lung Cancer. 2017;104:31–37. doi:10.1016/j.lungcan.2016.12.00328212997
   PubMed Web of Science ®Google Scholar